Showing 341-350 of 1321 results for "".
- Medimetriks Streamlines MM36 AD Development Programhttps://practicaldermatology.com/news/medimetriks-streamlines-mm36-ad-development-program/2460532/Medimetriks Pharmaceuticals, Inc. is moving forward with its MM36 (difamilast) Atopic Dermatitis Development Program following a meeting with the U.S. Food and Drug Administration (FDA). Medimetriks is now preparing to conduct a s
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Health Canada Approves Two New Gynecological Indications For Candela’s CO2RE Laser Platformhttps://practicaldermatology.com/news/health-canada-approves-two-new-gynecological-indications-for-candelas-co2re-laser-platform/2460434/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a single CO2 platform equipped w
- AAD Offers Tips for Practicing in the Era of COVID-19https://practicaldermatology.com/news/aad-offers-tips-for-practicing-in-the-era-of-covid-19/2460313/The American Academy of Dermatology released new guidance for dermatologists amid the COVID-19 crisis including an update on teledermatology and reimbursement codes. The guidance includes: March 19th AAD President’s Message:
- Cynosure's Four-Mode RF Microneedling Device Cleared for Marketinghttps://practicaldermatology.com/news/cynosures-four-mode-rf-microneedling-device-cleared-for-marketing/2460289/The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device. The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz
- Burt's Bees: Data Support Efficacy of Natural Skincarehttps://practicaldermatology.com/news/burts-bees-data-support-efficacy-of-natural-skincare/2460166/Products and ingredients in the Burt’s Bees natural skincare line provide documented benefits, according to studies presented at the second annual Integrative Dermatology Symposium (IDS) in San Diego this month. Among the findings is evidenc
- International Council Of Dermatologists Introduces New Method Of Determining Psoriasis Severityhttps://practicaldermatology.com/news/international-council-of-dermatologists-introduces-new-method-of-determining-psoriasis-severity/2460155/A new method to classify psoriasis severity can determine the appropriate course of treatment, according to a consensus paper by the International Psoriasis Council (IPC). The paper is published in the Journal of the American Academy of Dermatology. “There's
- Scaravoid May Offer A New Approach to Wound Healinghttps://practicaldermatology.com/news/scaravoid-may-offer-a-new-approach-to-wound-healing/2460126/A new foam that is placed in skin wounds to support and optimize the natural healing process may help prevent scarring. With the "Scaravoid" project, Markus Rottmar, PhD and his team at Empa's Biointerfaces lab
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Bo
- BioPharmX’s BPX-04 Performs Well in Rosacea Trialhttps://practicaldermatology.com/news/biopharmxs-bpx-04-performs-well-in-rosacea-trial/2460078/BioPharmX Corporation ‘s BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea, performed well in a Phase 2b clinical trial, the Company reports. In the trial,